Lung cancer survivors at high risk for recurrence, new lung cancer
the ONA take:
According to a new study presented at the American Thoracic Society (ATS) 2015 International Conference in Denver, Colorado, researchers have found that many lung cancer survivors are at high risk for developing recurrence of their disease or developing another another lung cancer.
For the study, researchers identified 192 lung cancer survivors who underwent surveillance for an average duration of about 8.5 years. Results showed that 38% of patients had developed recurrence or a new lung cancer during this period.
Researchers also found that for every additional pack of cigarettes smoked per year, patients had a 1% increased risk for developing lung cancer again. Other significant risk factors included presence of a nodule on a CT chest scan, premalignant lesions on three autofluorescence bronchoscopy exams anywhere in the central airway, and having recurrence of another non-lung cancer.
"We looked closely at risk factors that may help in predicting cancer recurrence in lung cancer survivors," said study lead author Samjot Dhillon, MD. "What we learned is that patients with a history of lung cancer should have close long-term surveillance so their doctor can detect early on if the cancer is recurring or if there is another cancer developing."
Many lung cancer survivors are at high risk for developing recurrence of their disease or developing another another lung cancer.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Pediatric Hepatocellular Carcinoma: Challenges and Solutions
- Earlier and Later Adult BMI Associated With Multiple Myeloma Risk
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- VBPWPs Can Compliment Patient Management in Clinical Trials
- Communication Technology Improves Treatment Burden, Patient Perspective of Oncology Care
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|